v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Change in the Carrying Value of Equity Method Investment (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 29, 2024
Jun. 30, 2024
Dec. 31, 2024
Schedule of Equity Method Investments [Line Items]      
Reclassification of accumulated other comprehensive income balances in Equity-method investments [1]     $ (143)
Transfer of carrying value to Short-term investments [2]     (5,411)
Ending carrying value     217
Haleon [Member]      
Schedule of Equity Method Investments [Line Items]      
Beginning carrying value reported in Equity-method investments     11,451
Carrying value of shares sold     (6,113)
Dividends     (212)
Currency translation adjustments and other [3]     341
Basis difference adjustments and amortization [4],[5]     (91)
Pfizer share of Haleon investee capital transaction $ 46 $ (91) (44) [4],[6]
Pfizer share of Haleon earnings [4]     224
Ending carrying value     $ 0
[1] Activity primarily represents foreign currency translation balances in accumulated other comprehensive income related to the equity-method investment in Haleon that were reclassified into equity-method investments upon our loss of significant influence over Haleon and our discontinuance of the equity method for the Haleon investment.
[2] The final carrying value of our equity-method investment in Haleon was reclassified to Short-term investments and was accounted for as an equity investment with a readily determinable fair value, until its disposition in the first quarter of 2025.
[3] See Note 6.
[4] Included in Other (income)/deductions––net.
[5] Adjustments include (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities.
[6] Includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an increase of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer’s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon’s second quarter 2024 financial statements.